BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 7509535)

  • 1. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
    Soloway MS; Hachiya T; Civantos F; Murphy WM; Gomez CC; Ruiz HE
    Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen.
    Soloway MS; Hachiya T; Ruiz HE; Gomez CC; Civantos F
    World J Urol; 1993; 11(4):221-6. PubMed ID: 7508788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F; Kaplan M; Soloway MS
    Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
    Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
    Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
    Oesterling JE; Andrews PE; Suman VJ; Zincke H; Myers RP
    J Urol; 1993 Apr; 149(4):779-82. PubMed ID: 7681117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
    Voges GE; Mottrie AM; Fichtner J; Mappes C; Störkel S; Stöckle M; Hohenfellner R
    Eur Urol; 1995; 28(3):209-14. PubMed ID: 8536774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].
    Miyamae K; Kitani K; Miyamoto K; Hamada S; Kawano T; Maehara A; Otsuka Y; Otsuka T; Hamada Y
    Nihon Hinyokika Gakkai Zasshi; 2009 Jul; 100(5):570-5. PubMed ID: 19663244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant androgen deprivation therapy before radical prostatectomy: who is unlikely to benefit?
    Rabbani F; Sullivan LD; Goldenberg SL; Stothers L
    Br J Urol; 1997 Feb; 79(2):221-5. PubMed ID: 9052474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
    Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
    Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
    Soloway MS; Sharifi R; Wajsman Z; McLeod D; Wood DP; Puras-Baez A
    J Urol; 1995 Aug; 154(2 Pt 1):424-8. PubMed ID: 7541859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.
    Lee F; Siders DB; McHug TA; Solomon MH; Klamerus ML
    Anticancer Res; 1997; 17(3A):1507-10. PubMed ID: 9179187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
    Tunn UW; Acar O; Goldschmidt AJ
    Urol Int; 1996; 56 Suppl 1():6-12. PubMed ID: 8776811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.